top glp 1 providers Decoding GLP-1 Weight Loss Medications Discover Magazine | Learn more

The combination of keto and GLP-1 represents one of the most promising approaches to sustainable fat loss with muscle preservation available, but it demands respect, planning, and ongoing attention to detail

10.1111/dom.13129 5

In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]

(n.d.-a)

Does the answer depend on preexisting patient-related factors that we are unaware of as of now